Which has preferable earnings & valuation, IPHA or CADL?

Candel Therapeutics has lower revenue, but higher earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $4.23M 46.47 -$55.64M N/A N/A Candel Therapeutics N/A N/A -$38.18M -$1.41 N/A

Is IPHA or CADL more profitable?

Innate Pharma's return on equity of 0.00% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Innate Pharma N/A N/A N/A Candel Therapeutics N/A -76.98% -48.50%

Does the media refer more to IPHA or CADL?

In the previous week, Innate Pharma had 9 more articles in the media than Candel Therapeutics. MarketBeat recorded 16 mentions for Innate Pharma and 7 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.75 beat Innate Pharma's score of 0.63 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ACRS or IPHA?

Innate Pharma has lower revenue, but higher earnings than Aclaris Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aclaris Therapeutics $7.83M 93.93 -$64.92M -$0.58 N/A Innate Pharma $4.23M 46.47 -$55.64M N/A N/A

Does the media favor ACRS or IPHA?

In the previous week, Innate Pharma had 13 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Innate Pharma and 3 mentions for Aclaris Therapeutics. Innate Pharma's average media sentiment score of 0.63 beat Aclaris Therapeutics' score of 0.29 indicating that Innate Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innate Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, SLN or IPHA?

Innate Pharma has higher revenue and earnings than Silence Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Silence Therapeutics $560K 1,237.53 -$88.61M -$1.28 N/A Innate Pharma $4.23M 46.47 -$55.64M N/A N/A

Does the media prefer SLN or IPHA?

In the previous week, Innate Pharma had 14 more articles in the media than Silence Therapeutics. MarketBeat recorded 16 mentions for Innate Pharma and 2 mentions for Silence Therapeutics. Innate Pharma's average media sentiment score of 0.63 beat Silence Therapeutics' score of 0.25 indicating that Innate Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silence Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Innate Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, IPHA or DBVT?

Innate Pharma has higher earnings, but lower revenue than DBV Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $4.23M 46.47 -$55.64M N/A N/A DBV Technologies $5.64M 135.68 -$146.95M -$3.51 N/A

Does the media refer more to IPHA or DBVT?

In the previous week, Innate Pharma had 14 more articles in the media than DBV Technologies. MarketBeat recorded 16 mentions for Innate Pharma and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.71 beat Innate Pharma's score of 0.63 indicating that DBV Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DBV Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, IPHA or PHAR?

Pharming Group has higher revenue and earnings than Innate Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innate Pharma $4.23M 46.47 -$55.64M N/A N/A Pharming Group $376.13M 2.03 $2.85M $0.12 89.75

Does the media refer more to IPHA or PHAR?

In the previous week, Innate Pharma had 10 more articles in the media than Pharming Group. MarketBeat recorded 16 mentions for Innate Pharma and 6 mentions for Pharming Group. Innate Pharma's average media sentiment score of 0.63 beat Pharming Group's score of 0.60 indicating that Innate Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innate Pharma 2 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Innate Pharma (IPHA) Competitors

$1.76 -0.04 (-2.22%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$1.77 +0.01 (+0.62%)

As of 04:35 AM Eastern

Compare

IPHA vs. CADL, ACRS, SLN, DBVT, and PHAR

Should you buy Innate Pharma stock or one of its competitors? Innate Pharma's main competitors and comparable companies include Candel Therapeutics (CADL), Aclaris Therapeutics (ACRS), Silence Therapeutics (SLN), DBV Technologies (DBVT), and Pharming Group (PHAR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Innate Pharma compare to Candel Therapeutics?

Innate Pharma (NASDAQ:IPHA) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

Innate Pharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.48, indicating that its stock price is 148% less volatile than the broader market.

Innate Pharma's return on equity of 0.00% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Candel Therapeutics	N/A	-76.98%	-48.50%

Innate Pharma currently has a consensus target price of $6.67, indicating a potential upside of 278.79%. Candel Therapeutics has a consensus target price of $20.14, indicating a potential upside of 78.41%. Given Innate Pharma's higher probable upside, analysts clearly believe Innate Pharma is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Candel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Innate Pharma had 9 more articles in the media than Candel Therapeutics. MarketBeat recorded 16 mentions for Innate Pharma and 7 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.75 beat Innate Pharma's score of 0.63 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics has lower revenue, but higher earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$4.23M	46.47	-$55.64M	N/A	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

0.2% of Innate Pharma shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 31.9% of Innate Pharma shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Innate Pharma beats Candel Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Innate Pharma compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Aclaris Therapeutics currently has a consensus target price of $11.33, suggesting a potential upside of 115.46%. Innate Pharma has a consensus target price of $6.67, suggesting a potential upside of 278.79%. Given Innate Pharma's higher probable upside, analysts plainly believe Innate Pharma is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	3.11
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Innate Pharma had 13 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 16 mentions for Innate Pharma and 3 mentions for Aclaris Therapeutics. Innate Pharma's average media sentiment score of 0.63 beat Aclaris Therapeutics' score of 0.29 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innate Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innate Pharma has lower revenue, but higher earnings than Aclaris Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	93.93	-$64.92M	-$0.58	N/A
Innate Pharma	$4.23M	46.47	-$55.64M	N/A	N/A

Aclaris Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -921.50%. Innate Pharma's return on equity of 0.00% beat Aclaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-921.50%	-61.65%	-42.41%
Innate Pharma	N/A	N/A	N/A

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 0.2% of Innate Pharma shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 31.9% of Innate Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Innate Pharma beats Aclaris Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Innate Pharma compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Innate Pharma (NASDAQ:IPHA) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Innate Pharma has higher revenue and earnings than Silence Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silence Therapeutics	$560K	1,237.53	-$88.61M	-$1.28	N/A
Innate Pharma	$4.23M	46.47	-$55.64M	N/A	N/A

Silence Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Innate Pharma has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to Silence Therapeutics' net margin of -8,943.86%. Innate Pharma's return on equity of 0.00% beat Silence Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silence Therapeutics	-8,943.86%	-106.94%	-47.99%
Innate Pharma	N/A	N/A	N/A

Silence Therapeutics presently has a consensus target price of $53.50, indicating a potential upside of 364.81%. Innate Pharma has a consensus target price of $6.67, indicating a potential upside of 278.79%. Given Silence Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Silence Therapeutics is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silence Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Innate Pharma had 14 more articles in the media than Silence Therapeutics. MarketBeat recorded 16 mentions for Innate Pharma and 2 mentions for Silence Therapeutics. Innate Pharma's average media sentiment score of 0.63 beat Silence Therapeutics' score of 0.25 indicating that Innate Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Silence Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Innate Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

98.7% of Silence Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Innate Pharma shares are held by institutional investors. 3.0% of Silence Therapeutics shares are held by company insiders. Comparatively, 31.9% of Innate Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Innate Pharma beats Silence Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Innate Pharma compare to DBV Technologies?

Innate Pharma (NASDAQ:IPHA) and DBV Technologies (NASDAQ:DBVT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, earnings and media sentiment.

Innate Pharma currently has a consensus target price of $6.67, indicating a potential upside of 278.79%. DBV Technologies has a consensus target price of $48.50, indicating a potential upside of 298.52%. Given DBV Technologies' higher possible upside, analysts plainly believe DBV Technologies is more favorable than Innate Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
DBV Technologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Innate Pharma has higher earnings, but lower revenue than DBV Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$4.23M	46.47	-$55.64M	N/A	N/A
DBV Technologies	$5.64M	135.68	-$146.95M	-$3.51	N/A

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 1.1% of DBV Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Innate Pharma has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market. Comparatively, DBV Technologies has a beta of -0.95, meaning that its stock price is 195% less volatile than the broader market.

Innate Pharma has a net margin of 0.00% compared to DBV Technologies' net margin of -3,506.53%. Innate Pharma's return on equity of 0.00% beat DBV Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
DBV Technologies	-3,506.53%	-119.33%	-84.43%

In the previous week, Innate Pharma had 14 more articles in the media than DBV Technologies. MarketBeat recorded 16 mentions for Innate Pharma and 2 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.71 beat Innate Pharma's score of 0.63 indicating that DBV Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DBV Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Innate Pharma beats DBV Technologies on 8 of the 13 factors compared between the two stocks.

How does Innate Pharma compare to Pharming Group?

Innate Pharma (NASDAQ:IPHA) and Pharming Group (NASDAQ:PHAR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

0.2% of Innate Pharma shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 31.9% of Innate Pharma shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Pharming Group has a net margin of 2.51% compared to Innate Pharma's net margin of 0.00%. Pharming Group's return on equity of 3.40% beat Innate Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innate Pharma	N/A	N/A	N/A
Pharming Group	2.51%	3.40%	1.90%

Innate Pharma has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Pharming Group has a beta of 0.01, indicating that its share price is 99% less volatile than the broader market.

In the previous week, Innate Pharma had 10 more articles in the media than Pharming Group. MarketBeat recorded 16 mentions for Innate Pharma and 6 mentions for Pharming Group. Innate Pharma's average media sentiment score of 0.63 beat Pharming Group's score of 0.60 indicating that Innate Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innate Pharma	2 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Innate Pharma presently has a consensus target price of $6.67, indicating a potential upside of 278.79%. Pharming Group has a consensus target price of $38.67, indicating a potential upside of 259.02%. Given Innate Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Innate Pharma is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innate Pharma	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pharming Group	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Pharming Group has higher revenue and earnings than Innate Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innate Pharma	$4.23M	46.47	-$55.64M	N/A	N/A
Pharming Group	$376.13M	2.03	$2.85M	$0.12	89.75

Summary

Innate Pharma beats Pharming Group on 9 of the 14 factors compared between the two stocks.

Get Innate Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IPHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IPHA vs. The Competition

Export

Metric	Innate Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$201.09M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	N/A	13.88	274.09	25.69
Price / Sales	46.47	1,353.16	642.55	79.71
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-6.77	15.40	10.47	6.32
Net Income	-$55.64M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-7.85%	-1.74%	-0.68%	0.17%
1 Month Performance	-20.00%	-6.20%	-3.18%	-3.27%
1 Year Performance	-3.24%	30.64%	15.12%	5.58%

Innate Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IPHA Innate Pharma	4.0925 of 5 stars	$1.76 -2.2%	$6.67 +278.8%	-3.0%	$201.09M	$4.23M	N/A	163	Trending News Analyst Forecast Analyst Revision
CADL Candel Therapeutics	3.7316 of 5 stars	$11.12 +4.1%	$19.29 +73.4%	+113.4%	$816.84M	N/A	N/A	55	Analyst Upgrade
ACRS Aclaris Therapeutics	1.9745 of 5 stars	$5.53 -2.0%	$11.33 +104.9%	+187.4%	$788.61M	$7.83M	N/A	73	Analyst Forecast
SLN Silence Therapeutics	2.3944 of 5 stars	$12.46 -4.6%	$53.50 +329.4%	+123.5%	$786.33M	$560K	N/A	88
DBVT DBV Technologies	3.4461 of 5 stars	$11.76 -4.8%	$48.50 +312.4%	+30.2%	$776.54M	$5.64M	N/A	161

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IPHA) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Innate Pharma (IPHA) Competitors

IPHA vs. CADL, ACRS, SLN, DBVT, and PHAR

How does Innate Pharma compare to Candel Therapeutics?

Summary

How does Innate Pharma compare to Aclaris Therapeutics?

Summary

How does Innate Pharma compare to Silence Therapeutics?

Summary

How does Innate Pharma compare to DBV Technologies?

Summary

How does Innate Pharma compare to Pharming Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Innate Pharma (IPHA) Competitors

IPHA vs. CADL, ACRS, SLN, DBVT, and PHAR

How does Innate Pharma compare to Candel Therapeutics?

Which has more volatility and risk, IPHA or CADL?

Is IPHA or CADL more profitable?

Do analysts prefer IPHA or CADL?

Does the media refer more to IPHA or CADL?

Which has preferable earnings & valuation, IPHA or CADL?

Do institutionals and insiders have more ownership in IPHA or CADL?

Summary

How does Innate Pharma compare to Aclaris Therapeutics?

Do analysts rate ACRS or IPHA?

Does the media favor ACRS or IPHA?

Which has preferable valuation and earnings, ACRS or IPHA?

Which has more volatility & risk, ACRS or IPHA?

Is ACRS or IPHA more profitable?

Do insiders & institutionals hold more shares of ACRS or IPHA?

Summary

How does Innate Pharma compare to Silence Therapeutics?

Which has higher earnings and valuation, SLN or IPHA?

Which has more risk & volatility, SLN or IPHA?

Is SLN or IPHA more profitable?

Do analysts rate SLN or IPHA?

Does the media prefer SLN or IPHA?

Do insiders and institutionals hold more shares of SLN or IPHA?

Summary

How does Innate Pharma compare to DBV Technologies?

Do analysts rate IPHA or DBVT?

Which has higher valuation & earnings, IPHA or DBVT?

Do institutionals and insiders believe in IPHA or DBVT?

Which has more risk and volatility, IPHA or DBVT?

Is IPHA or DBVT more profitable?

Does the media refer more to IPHA or DBVT?

Summary

How does Innate Pharma compare to Pharming Group?

Do insiders & institutionals believe in IPHA or PHAR?

Is IPHA or PHAR more profitable?

Which has more volatility & risk, IPHA or PHAR?

Does the media refer more to IPHA or PHAR?

Do analysts rate IPHA or PHAR?

Which has better valuation and earnings, IPHA or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPHA vs. The Competition

Innate Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools